Across TCGA pan-cancer cohorts, MIR520B RNA is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MIR520B data layer compared with 4 for mutation status.
The strongest signal is observed in brain lower grade glioma (LGG), where higher MIR520B RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MIR520B expression acts as an unfavorable survival marker.
LGG and STAD are the cancer types where MIR520B RNA most reproducibly stratifies survival.